Posts

Cybin Set to Measure Psychedelic Effects on the Brain Using Kernel Flow’s Revolutionary Technology

Cybin Set to Measure Psychedelic Effects on the Brain Using Kernel Flow’s Revolutionary Technology

The technology may be more broadly used in the future for neuroscientific or physiological studies of brain activity during psychedelic use.

2021: A Year in Review for the Psychedelics Business

Our resident Psychedelic Investor looks back at some of this growing industry's biggest moments and how they may shape the business in 2022.
Psychedelic Business Spotlight – December 17

Psychedelic Business Spotlight – December 17

This week in psychedelic business news: Cybin steps closer to a new patent; MindMed appoints new CEO; MAPS and Wesana Health resume negotiations.

Psychedelic Business Spotlight: December 3

This week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.
Psychedelic Business Spotlight: November 26

Psychedelic Business Spotlight: November 26

This week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big money; Cybin makes psychedelic therapy more accessible in NYC.
Manhattan Hospital Partners with Cybin to Provide Psychedelic Therapies to Marginalized CoShutterstock.com

Manhattan Hospital Partners with Cybin to Provide Psychedelic Therapies to Marginalized Communities

“It’s time for psychedelic medicine to climb down from the ivory tower and into the community,” says Cybin Chief Clinical Officer Dr. Alex Belser.

Psychedelic Business Spotlight: November 12

This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO intention.
Could the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser

Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the ‘Superior Molecule’

Pre-clinical studies demonstrated multiple advantages, including less patient variability, faster onset of action, shorter duration of effect, and improved brain penetration.
Psychedelic Business Spotlight: November 5

Psychedelic Business Spotlight: November 5

This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
Could the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser

Can the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser

"Something that people used to speak about only in whispers is now standard policy," says the psychedelics researcher, with 20 years of experience, in a wide-ranging Q&A.